Man­u­fac­tur­ing roundup: Juno Phar­ma­ceu­ti­cals ac­quires Omega Lab­o­ra­to­ries; Pfiz­er halts dis­tri­b­u­tion of four med­i­cines

Juno Phar­ma­ceu­ti­cals has ac­quired the in­jectable phar­ma­ceu­ti­cal man­u­fac­tur­er Omega Lab­o­ra­to­ries.

The deal gives Juno one of Cana­da’s largest in­jectable man­u­fac­tur­ers, which is ex­pect­ed to trans­form it in­to one of Cana­da’s largest spe­cial­ty gener­ic in­jectable pro­duc­ers with do­mes­tic man­u­fac­tur­ing abil­i­ties.

Juno al­so plans to bring more than 100 new prod­ucts to Cana­da over the next four years, main­ly treat­ments for pain man­age­ment, al­ler­gies, and weight loss. Fi­nan­cial de­tails of the deal were not dis­closed.

Endpoints News

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters